














doi:10.101Hyperlipidemia and Statin Use after Allogeneic
Hematopoietic Stem Cell Transplantation
Bradley W. Blaser,1 Haesook T. Kim,2 Edwin P. Alyea, III,3 Vincent T. Ho,3 Corey Cutler,3
Philippe Armand,3 John Koreth,3 Joseph H. Antin,3 Jorge Plutzky,4 Robert J. Soiffer3An increased incidence of cardiovascular complications has been documented in recipients of allogeneic he-
matopoietic stem cell transplantation (HSCT). Despite this, little is known about the risk factors for hyper-
lipidemia or the role of lipid-lowering therapy early after transplantation. We performed a retrospective
analysis of all patients who underwent allogeneic HSCT at the Dana-Farber Cancer Institute from 1998 to
2008 and who survivedmore than 100 days. The incidence of hypercholesterolemia and hypertriglyceridemia
in the first 2 years after transplantation was 73.4% and 72.5%, respectively. In multivariable analysis, the de-
velopment of acute graft-versus-host disease was independently associated with both hypercholesterolemia
(odds ratio [OR] 5 1.62) and hypertriglyceridemia (OR 5 1.54) after transplantation. Statin use was insti-
tuted in 29% of patients and was associated with a significant net reduction in total cholesterol (65 mg/dL,
P\.0001), triglyceride (118 mg/dL P\.0001), and LDL levels (59 mg/dL P\.0001) without any significant
adverse effects. These data suggest that hyperlipidemia is common in the first 2 years after allogeneic trans-
plantation when most patients remain under the care of the transplantation physician and lipid-lowering ther-
apy may be underutilized. Given the cardiovascular risk associated with hyperlipidemia and the tolerability of
statins, further prospective evaluation of lipid abnormalities and their treatment seems well warranted.
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There is a growing appreciation that coronary artery
disease andmyocardial infarction are relatively common
late complications of allogeneic hematopoietic stem
cell transplantation (HSCT) [1-3]. Hyperlipidemia is a
well-known risk factor for atherosclerotic heart disease
[4]; several reports have documented the incidence of
hyperlipidemia and cardiovascular events late after
HSCT [1,3,5-8]. However, little is known about the
incidence of hyperlipidemia within the first 2 years. If1Department of Medicine, Brigham andWomen’s Hospi-
oston, Massachusetts; 2Department of Biostatistics and
utational Biology, Dana-Farber Cancer Institute, Boston,
chusetts; 3Division of Hematologic Malignancies,
Farber/Brigham and Women’s Cancer Center, Boston,
chusetts; and 4Division of Cardiovascular Medicine,
am and Women’s Hospital, Boston, Massachusetts.
isclosure: See Acknowledgments on page 582.
dence and reprint requests: Robert J. Soiffer, MD,
Farber Cancer Institute, 44 Binney Street, Dana 1B11,
n, MA 02115 (e-mail: robert_soiffer@dfci.harvard.edu).
une 24, 2011; accepted August 1, 2011
erican Society for Blood and Marrow Transplantation
/$36.00
6/j.bbmt.2011.08.003there is a characteristic pattern of changes in lipid
profiles early after transplantation, more aggressive
lipid modification therapy at that time may help
ameliorate late cardiovascular complications.
HMG-CoA reductase inhibitors (statins) are the
mainstay of treatment for hyperlipidemia, have salu-
tary effects on low-density lipoproetin (LDL), and
are widely used in the general population [9]. How-
ever, because of the concern of potential liver toxicity,
drug interactions, and monitoring for liver graft-
versus-host disease (GVHD), they are often discontin-
ued at the time of HSCT and may not be started after
transplantation. The reported rate of statin use in
HSCT patients ranges from 5% to 15% in previously
reported series, although it is unclear whether their use
is safe and/or effective in this setting [10-12].
We performed a retrospective chart review on all
patients who underwent allogeneic HSCT at the
Dana-Farber Cancer Institute/Brigham andWomen’s
Hospital from 1998 to 2008, survived more than
100 days posttransplantation, and had lipid measure-
ments after transplantation.We describe the incidence
and time course of hyperlipidemia after allogeneic
HSCT, identify risk factors for hyperlipidemia,
and examine the use and effect of statin therapy for
hyperlipidemia.575
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Patient Population
The subjects of this retrospective study were 1493
consecutive patients who underwent allogeneic HSCT
at the Dana-Farber Cancer Institute from 1998 to
2008 and who survived more than 100 days following
transplantation. A total of 732 subjects had no total
cholesterol measurements from day 30 to 2 years after
transplantation and were excluded from the analysis.
Patients were treated according to investigational pro-
tocol, if applicable, or institutional standard of care.
Myeloablative conditioning regimens included cyclo-
phosphamide (1800 mg/m2  2 days) plus total body
irradiation (14 Gy total in 7 fractions over 4 days) or
busulfan (16 mg/kg orally or 12.8 mg/kg intravenously
total) in 16 divided doses. Reduced-intensity condi-
tioning regimens consisted of fludarabine (30 mg/m2
intravenously) and busulfan (0.8 or 1.6 mg/kg intrave-
nously) for 4 days. GVHD prophylaxis consisted
predominantly of a calcineurin inhibitor and metho-
trexate, tacrolimus plus sirolimus with or without
low dose methotrexate, or ex vivo T cell depletion
with or without additional immune suppression. Lipid
profiles were analyzed by standard methods either at
the discretion of the primary transplantation physician
or according to protocol. Routine practice was for lipid
profiles to be drawn after a minimum 9-hour fast.
This retrospective analysis was approved by the
Office for the Protection of Research Subjects at the
Dana-Farber Cancer Institute.
Data Extraction
Patient and donor characteristics, stem cell source,
conditioning and prophylactic regimens, and inci-
dence and severity of acute and chronic GVHD
(aGVHD, cGVHD) were retrieved from the bone
marrow transplant data repository at the Dana-
Farber Cancer Institute. Lipid values and outpatient
medication history were accessed via an electronic
medical record system covering more than 10 hospitals
and associated clinics in the greater Boston area.
Hyperlipidemia was defined as any outpatient total
cholesterol value $200 mg/dL or triglyceride value
$200mg/dL. These cutoffs were derived from current
treatment guidelines [4]. Lipid values obtained within
30 days of transplantation were excluded from the
statistical analysis. Patients with any 30-day prescrip-
tion for a statin listed among their current or discon-
tinued medications were considered to have been
treated with statins. Only prescriptions starting from
day 0 to 2 years after transplantation were considered.
Statistical Analysis
Patient baseline characteristics were reported de-
scriptively and the chi-square test or the Wilcoxonrank sum test was used for group comparison. Differ-
ences in lipid levels between pre- and posttransplanta-
tion measurements were tested using the Wilcoxon
signed rank test. Whether the status of hyperlipidemia
was in agreement before and after transplantation was
tested using McNemar’s test. Cumulative incidence of
aGVHD and cGVHD was calculated reflecting time
to relapse or death without developing GVHD as
a competing risk. The difference between cumulative
incidence curves in the presence of a competing risk
was tested using the Gray method. Potential prognos-
tic factors for hyperlipidemia after HSCT were exam-
ined in the univariable and multivariable logistic
regression analysis. The functional form of year of
transplantation was examined using restricted cubic
spline function [13]. All tests were 2 sided. All calcula-
tions were performed using SAS 9.2 (SAS Institute,
Cary, NC) and R 2.10.1 (The CRAN project).RESULTS
Patient Characteristics
The characteristics of the patients included in the
study are detailed in Table 1. Among the 761 patients
included in the study, median age at transplantation
was 49 years (range: 17-73), 60% had myeloid
neoplasms, 42% received grafts from matched related
donors, 46% from matched unrelated donors, and
55% received myeloablative conditioning. Greater
than 95% of patients received tacrolimus-based
GVHD prophylaxis. Sirolimus was included as
GVHD prophylaxis for 50%. The cumulative inci-
dence of grade II to IV aGVHD was 26% at 200
days after transplantation; the cumulative incidence
of cGVHD at 2 years after transplantation was 60%
(Table 2). Also listed in Tables 1 and 2 are the
baseline characteristics and cumulative incidence of
GVHD for 732 excluded patients who underwent
HSCT within the same time period, were alive at day
100, but did not have lipid values checked within
2 years after transplantation. The patients who had
lipid values checked were older (P 5 .001), more
likely to be male (P 5 .016), more likely to have
received peripheral blood stem cell grafts (P\ .001),
more likely to have received sirolimus-based GVHD
prophylaxis (P\ .001), more likely to have received
reduced-intensity conditioning regimens (P 5 .047),
and were more likely to be overweight (P 5 .02) com-
pared with patients who did not have their lipid values
checked (Table 1). Lipid values were checked more
frequently in the year 2002 and later than before
2002 (P\ .001) (Table 1). There was no difference
in the cumulative incidence of aGVHD at 200 days
after transplantation in either group, although
cGVHD was more common in those who had their
lipids checked (P\ .001) (Table 2).
Table 1. Table of Baseline and Transplant Characteristics for





N % N % P
Age at HSCT .001
<50 397 52 444 61
$50 364 48 288 39
Median age (range) 49 (17*-73) 46 (18-73) .001
Patient gender .016
M 462 61 399 55
F 299 39 333 45
Patient–donor gender .046
M<-F 201 26 160 22
other 560 74 572 78
Donor type .21
Matched unrelated 350 46 299 41
Matched related 322 42 343 47
Mismatched unrelated 80 11 78 11
Mismatched related 9 1 12 2
Cell source <.001
Bone marrow 146 19 258 35
PBSC 575 76 444 61
Cord blood 36 5 30 4
Acute GVHD prophylaxis <.001
Sirolimus-containing 384 50 248 34
No sirolimus 377 50 484 66
Conditioning regimen .047
Myeloablative 419 55 441 60
RIC 342 45 291 40
Diagnosis .38
Myeloid malignancy 455 60 412 56
Lymphoid malignancy 272 36 298 41
Other 34 4 22 3
Body mass index (BMI) at HSCT .048
median (range) 27 (16-65) 26 (17-69)
Overweight at HSCT (BMI $ 25) .02
No 254 33 287 39
Yes 507 67 445 61
Obese at HSCT (BMI $ 30) .77
No 552 73 536 73
Yes 209 27 196 27
PBSC indicates peripheral blood stem cell; RIC, reduced-intensity
conditioning.
*One patient was 17 years 9 months at the time of HSCT.
Table 3. Frequency of Hyperlipidemia in Allogeneic HSCT
Recipients
Pretransplantation Posttransplantation
N % N %
Total cholesterol
0-199 mg/dL 381 68.0 201 26.6
$200 mg/dL 179 32.0 556 73.4
Triglyceride
0-199 mg/dL 348 60.7 201 27.5
$200 mg/dL 225 39.3 531 72.5
Cutoffs were derived from current ATP-III treatment guidelines.
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Of the 761 patients included in the study, 556
(73.4%) had at least 1 posttransplantation total choles-
terol value $200 mg/dL and were considered hyper-
cholesterolemic according to the ATP-III treatment
guidelines (Table 3). Five hundred sixty patients also
had at least 1 total cholesterol value recorded in the
90 days before transplantation. Of these, 179 (32.0%)
were hypercholesterolemic before transplantationTable 2. Cumulative Incidence of aGVHD and cGVHD for
Patients Included and Excluded from the Study
Included Excluded P
aGVHD Grade II-IV
100 day CI 23% 26% .43
200 day CI 26% 28%
cGVHD
1 year CI 53% 42% <.001
2 year CI 60% 47%(Table 3). Among the 560 patients with both pre- and
posttransplantation values, the median peak total cho-
lesterol levels before and after transplantation were
178 and 241 mg/dL, respectively (pre–post change:
62 mg/dL, P\ .0001 (Figure 1A). Posttransplantation
hypertriglyceridemia (defined as any triglyceride mea-
surement $200 mg/dL) was present in 531 patients
(72.5%) (Table 3). Five hundred seventy-three patients
had pretransplantation triglyceride levels measured.
Of these, 225 (39.3%) were hypertriglyceridemic
(Table 3). The number of patients with both pre- and
posttransplantation triglyceride values was 554; among
these, the median peak triglyceride levels before and
after transplantation were 171 and 275 mg/dL, respec-
tively (pre–post change: 109 mg/dL, P \ .0001)
(Figure 1B). Compiled total cholesterol and triglycer-
ide values for the first 2 years after transplantation are
presented in Figure 1C and 1D.
Comparison of Hyperlipidemia before and after
Transplantation
To clarify the changes in lipid levels occurring with
transplantation,we identifiedpatientswhohadpreexist-
ing hyperlipidemia and those who had de novo hyperli-
pidemia after transplantation. Among 179 patients with
preexisting hypercholesterolemia, 164 patients (92%)
remained hypercholesterolemic after transplantation.
Of the 381 patients with pretransplant total cholesterol
\200mg/dL, 249 patients (65%) became newly hyper-
cholesterolemic after transplantation. Among patients
who experienced a change in their status (hypercholes-
terolemic or not) before and after transplantation, 94%
developed de novo hypercholesterolemia (P \ .001;
McNemar’s test). For patients with preexisting hyper-
cholesterolemia, total cholesterol was higher after
transplantation compared with those who had de novo
hypercholesterolemia after transplantation (275mg/dL
versus 259 mg/dL, P5 .004).
Among 216 patients with preexisting hypertrigly-
ceridemia, 193 patients (89%) remained hypertrigly-
ceridemic after transplantation. Of the 338 patients
with pretransplantation triglyceride\200 mg/dL, 215
patients (64%) became newly hypertriglyceridemic after
transplantation. Among patients who experienced a
change in their status (hypertriglyceridemic or not)
Figure 1. (A, B) Box and whisker plots demonstrating peak total cholesterol (A, N5 560) and triglyceride (B, N5 554) values within the first 90 days
before transplantation (pre) and 30 days to 2 years after transplantation (post). Only patients with both pre- and posttransplantation values are included
in Figures 1A and 1B. (C, D) Box andwhisker plots demonstrating compiled total cholesterol and triglyceride levels from all patients included in the study.
578 Biol Blood Marrow Transplant 18:575-583, 2012B. W. Blaser et al.before and after transplantation, 90% developed de
novo hypertriglyceridemia (P \ .001; McNemar’s
test). For patients with preexisting hypertriglyceride-
mia, triglyceride values were higher after transplanta-
tion compared with those who had de novo
hypertriglyceridemia after transplantation (398 mg/
dL versus 305 mg/dL, P\ .001).
To confirm that pretransplantation lipid levels
were drawn on a random subset of patients, the rate
of posttransplantation hypercholesterolemia and
hypertriglyceridemia for those with and without pre-
transplantation lipids were compared. There was no
difference in the rate of posttransplantation hypercho-
lesterolemia for patientswith andwithoutpretransplan-
tation values (74% versus 73%, P 5 .75). Similarly,
there was no difference in the rate of posttransplanta-
tion hypertriglyceridemia for patients with and without
pretransplantation values (74% versus 69%, P5 .24).
Risk Factors for Hyperlipidemia
To identify risk factors for posttransplantation hy-
perlipidemia, patients with at least 1 total cholesterol
$200 mg/dL or triglyceride $200 mg/dL from day
30 to 2 years after transplantation were identified.
Logistic regression analysis was performed using base-
line patient characteristics (age$50, male gender, type
of malignancy, overweight [body mass index $25]),
transplantation variables (unrelated or mismatched
donor, stem cell source, conditioning regimen
intensity, sirolimus-based GVHD prophylaxis), andposttransplantation variables (presence of grade II-IV
aGVHD). In univariable analysis, being overweight
at the time of transplantation and the development of
grade II to IV aGVHDwere associated with both post-
transplantation hypercholesterolemia and hypertrigly-
ceridemia (data not shown).Male gender and sirolimus
use were associated only with posttransplantation
hypertriglyceridemia (data not shown).
Multivariable logistic regression analysis was also
performed using similar variables in the model
(Figure 2A-B). There was a strong inverse correlation
between sirolimus use and the presence of acute
GVHD, so sirolimus use was not included in the
model. The development of grade II to IV aGVHD
was an independent risk factor for both posttransplan-
tation hypercholesterolemia and hypertriglyceridemia
(odds ratio [OR] 5 1.62, P 5 .02 and OR 5 1.54,
P 5 .036, respectively) as was being overweight at
the time of transplantation (OR 5 1.64, P 5 .0063
and OR 5 2.12, P\ .0001, respectively). Male recipi-
ents (OR 5 0.67, P 5 .03) and those receiving bone
marrow allografts (OR5 0.57, P5 .02) were less likely
to have posttransplantation hypercholesterolemia
compared with female recipients or those receiving
peripheral blood stem cell allografts.
Hyperlipidemia in Patients with aGVHD
Among the patients with grade 0 to I aGVHD, the
frequency of posttransplantation hypercholesterol-
emia was 71%, whereas among patients with grade II
Figure 2. Multivariable analysis for odds ratio identifying risk factors for peak posttransplantation total cholesterol $200 mg/dL (A) or triglyceride
$200 mg/dL (B). Error bars represent 95% confidence intervals.
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patients with grade 0 to I aGVHD, the frequency of
posttransplantation hypertriglyceridemia was 70%,
whereas among patients with grade II to IV aGVHD
the frequency was 79% (P 5 .01). The median peak
total cholesterol level was 235 mg/dL for patients
with grade 0 to I aGVHD and 262 mg/dL for patients
with grade II to IV aGVHD (P\ .001). The median
peak triglyceride level was 264 mg/dL for patients
with grade 0 to I aGVHD and 300 mg/dL for patients
with grade II to IV aGVHD (P 5 .002).
Corticosteroid therapy is known to elevate serum
lipids. Of the hypercholesterolemic patients with
grade II to IV aGVHD, 81% were being treated
with steroids at the time of their peak total cholesterol
measurement. Of the hypertriglyceridemic patients
with grade II to IV aGVHD, 73% were being treated
with steroids at the time of their peak triglyceride
measurement.Statin Usage after Transplantation
Outpatient prescription records of the 761 patients
in the study were searched for the presence of any
statin medication. Sixty-two patients (8%) had been
prescribed any statin medication before transplanta-
tion. Among these, statin therapy was resumed in
53 patients after transplantation (85%). Overall,220 patients (29%) were prescribed statin therapy
within the first 2 years after transplantation. Atorvasta-
tin was the most frequently prescribed statin (54%),
followed by simvastatin (29%), pravastatin (8%), rosu-
vastatin (7%), lovastatin (2%), and fluvastatin (\1%).
The median day of initiation of statin therapy was
400 days after transplantation (range: 1-723 days).
Changes in lipid values were calculated for patients
who had values recorded in the 90 days before initia-
tion of statin therapy and who had values recorded
from 180 to 270 days following initiation of statin ther-
apy. Median values obtained immediately before and
after statin initiation are plotted in Figure 3 (total cho-
lesterol before statin: 255 mg/dL, after statin: 190 mg/
dL, N 5 94, P\ .0001; triglyceride before statin: 318
mg/dL, after statin: 200 mg/dL, N 5 91, P\ .0001;
HDL before statin: 45 mg/dL, after statin: 52 mg/
dL, N 5 76, P 5 .51; LDL before statin 158 mg/dL,
after statin 99 mg/dL, N 5 49, P\ .0001).
The medical records of the 220 statin-treated pa-
tients were reviewed for the presence of adverse drug
reactions leading to discontinuation of the statins. In
76 patients (35%), statin therapy had been discontin-
ued. The reasons for discontinuation included reach-
ing target LDL (N 5 11, 5% of all statin treated
patients), relapse of disease with reinduction chemo-
therapy or second transplantation (N 5 13, 6%), and
evidence of possible statin toxicity (N 5 7, 3%).
Figure 3. (A-D), Box and whisker plots demonstrating paired lipid values drawn up to 90 days before (pre) and 270 days after (post) starting statin
therapy. Total cholesterol (A, N 5 94 patients), triglyceride (B, N 5 91 patients), HDL (C, N 5 76 patients), and LDL (D, N 5 49 patients) values
are plotted.
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biopsy-proven aGVHD of the liver, 1 had suspected
aGVHD of the liver, and 1 had veno-occlusive disease
of the liver documented within the same time period as
the discontinuation of statin therapy. Only 1 patient
had elevation of liver enzymes attributed to statin ther-
apy, although themeasurements did not meet accepted
criteria for statin toxicity [14]. One patient had muscle
cramps without an elevation in creatine phosphokinase
and 1 patient had rhabdomyolysis with creatine phos-
phokinase5 3186 U/L. Four patients (2%) discontin-
ued statin therapy because of personal preference. In
41 patients (19% of all statin treated patients, 54% of
all discontinuations), the reason for discontinuation
of statin therapy was not documented in the medical
record. There was no clear evidence of statin liver tox-
icity or rhabdomyolysis in any of these 41 cases.DISCUSSION
Hyperlipidemia and atherosclerotic heart disease are
increasingly recognized as late complications of alloge-
neic HSCT [8,15]. Several small studies have reported
the incidence of posttransplantation hyperlipidemia to
range from 11% to 58% [1,5-7,16,17]. The incidence
of adverse cardiovascular events including myocardial
infarction and stroke may also be more common in
allogeneic HSCT recipients, particularly in those
with aGVHD, when compared with siblings or
recipients of autologous HSCT [1,3,18]. The present
study examines the early posttransplantation changes
in serum lipids in a large cohort of allogeneic HSCT
recipients. We have described a pattern of elevated
total cholesterol and triglyceride levels in the
patients who had their lipids measured within the
Biol Blood Marrow Transplant 18:575-583, 2012 581Hyperlipidemia after Allogeneic HSCTfirst 2 years after transplantation. In the largest series
of patients reported to date, we have demonstrated
that aGVHD is an independent risk factor for
both posttransplantation hypercholesterolemia and
hypertriglyceridemia. Statins appeared to be effective
in improving the lipid profiles in those in whom they
were used and the incidence of toxicity appeared to
be low. Whether early initiation of statin therapy
after allogeneic HSCT would be effective in
lowering the risk of cardiovascular events attributable
to transplantation is currently unknown.
As a retrospective study, our analysis has several in-
herent limitations. Because lipid panels were collected
at the discretion of outpatient providers, our results
may not accurately estimate the true incidence of hy-
perlipidemia in all HSCT recipients. In particular,
the group of patients who had their lipids checked
was older, more likely to be overweight, and more
likely to be male than the group of patients who did
not have their lipids checked. Total cholesterol and tri-
glyceride levels were chosen for the primary analyses
because these data were available in the majority of pa-
tients, whereas LDL levels were not. Although total
cholesterol and triglyceride levels are a part of the rec-
ommended cardiovascular risk assessment, therapeutic
goals are based on LDL levels [4]. Further, the medical
record did not allow verification that lipid panels were
drawn in the fasting state, although our routine prac-
tice has been for these labs to be drawn after a 9- to
12-hour fast. Because our institution draws from a
large referral base, some patients living farther away
from our center may have had their lipids checked
and managed locally. Their lipid measurements, pre-
scription history, and potential adverse reactions to
statins may not have been available for this study. In
addition, because .95% of our patient population re-
ceived tacrolimus for GVHD prophylaxis, we were un-
able to assess the contribution of this or cyclosporine
to hyperlipidemia. Finally, the association of aGVHD
with hyperlipidemia may be confounded by concomi-
tant steroid use in many cases.
In addition to their beneficial lipid-lowering ef-
fects, statins are known to possess anti-inflammatory
properties that likely contribute to their clinical bene-
fit. A large randomized, placebo-controlled trial of ro-
suvastatin in patients with normal lipid profiles showed
a reduction in C-reactive protein levels and improved
survival [19]. Several randomized studies of cardiac
transplantation recipients have demonstrated amortal-
ity benefit for statin use, and 2 have shown a decrease in
major cardiac allograft rejection by statins [20-24].
Similar findings have been made in lung and renal
allograft recipients, although not all studies have
shown benefit in the latter [25-28]. Further,
a number of trials in patients with rheumatoid
arthritis and multiple sclerosis have demonstrated
improved outcomes in patients treated with statins[29-33]. Thus, statins have a proven clinical benefit
in multiple settings as adjunctive immune suppressive
therapy.
Recent reports have begun to investigate the effect
of immunomodulation with statins in allogeneic
HSCT. A study in 2008 reported decreased incidence
of grade II to IV aGVHD in recipients who had been
on statins 1 month before transplantation and who
continued on them for 3 months after transplantation
[10]. A subsequent larger study showed decreased inci-
dence of aGVHD in recipients of grafts from statin-
treated donors [11]. Acute GVHD was not prevented
when statin treatment was limited to the recipient
alone. Recipient treatment was associated with de-
creased rates of cGVHD and an increased rate of
relapse or disease progression [12]. Interpretation of
these studies is confounded by the low rate of statin
use in recipients and the potential biased use of statin
therapy in patients free from complications of trans-
plantation for other reasons. The mechanism underly-
ing these observations is unknown, but in vitro and
animal studies suggest Th2 polarization of the donor
T cell pool may play a role [34,35].
With the growing body of evidence that statins
may be important as adjuvant immune suppressive
therapy and for controlling hyperlipidemia after trans-
plantation, it is necessary to consider the frequency
and efficacy of their use after HSCT. The frequency
of statin use in our population of patients was higher
when compared with prior studies (29% versus 15%
in Hamadani et al. [10] and 5% in Rotta et al. [11]).
The National Health and Nutrition Examination Sur-
vey study data shows a steady rise in statin use in the
general population from 6.5% of all U.S. adults in
1999 to 2000 to 11.7% in 2003 to 2004, the latest
available published data [9]. Because we required
only 1 month of statin use to qualify, our study may
overestimate the rate of statin use compared with these
other works. Despite this, the efficacy of statin use in
our study does not appear to be inferior to that seen
in the general population. According to National
Health and Nutrition Examination Survey data from
2003 to 2004, the average LDL of hyperlipidemic
U.S. adults in the absence or presence of statin therapy
was 158.4 mg/dL and 100.7 mg/dL, respectively,
which is consistent with our findings in Figure 3 [9].
There are a number of obvious barriers to statin use
after HSCT including interaction with other hepato-
toxic or hepatically metabolized medications, the poten-
tial for confounding the diagnosis of or worsening
aGVHD or veno-occlusive disease of the liver, and the
risk of inhibiting graft-versus-leukemia effects
[12,36,37]. Statins are routinely used in cardiac
transplantation, suggesting that their coadministration
with calcineurin inhibitors is safe, although the use of
azoles in such patients is much less common than in
the allogeneic HSCT population [21-23]. Further,
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and primary biliary cirrhosis have shown that statin
therapy is well tolerated in patients with chronic liver
disease [38-42]. Our data suggest that significant
adverse reactions to statin therapy are relatively
infrequent in the posttransplantation setting. Clearly,
close monitoring should accompany the use of these
medications in allogeneic HSCT patients.
These data provide the first detailed look at the
patterns of hyperlipidemia that occur early after
HSCT. They provide the strongest evidence to date
that aGVHD is an independent risk factor for hyper-
lipidemia. Current guidelines recommend screening
for hyperlipidemia in HSCT recipients at the same
frequency as in the general population [43]. These
guidelines were published before the cardiovascular
risks of HSCT were well appreciated and they do not
account for the rising age of the population undergo-
ing HSCT [1,3,8,44,45]. Our data lend further
support to the proposal of Griffith et al. [15] that lipid
profiles be assessed 4 weeks after transplantation and
then every 3 months while on immune suppressive
therapy. Clinicians should be particularly attuned to
lipid abnormalities in patients receiving sirolimus or
in those who develop GVHD. Nevertheless, the risks
and benefits of aggressive lipid-lowering therapy
have not yet been established in this population.
Several important questions remain: Is it safe to treat
to established LDL goals? What are the risks of statin
therapy?What role do statins play as adjuvant immune
suppression? How can non-LDL lipid goals be safely
achieved? Answering such questions will require a pro-
spective trial of the use of statins in allogeneic HSCT.ACKNOWLEDGMENTS
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